NCT00733122 2025-03-03
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
Clinical Trials
3 trialsNCT02082639 2015-07-20
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years
GlaxoSmithKline
Phase 3 Withdrawn
NCT02100618 2015-07-20
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
GlaxoSmithKline
Phase 3 Withdrawn